TREM2-mediated PV interneuron stabilization to restore gamma coherence in proteinopathy-driven neurodegeneration

The AD mechanism of PV interneuron targeting to restore theta-gamma coupling may transfer to neurodegeneration via TREM2-microglial modulation of GABAergic inhibition. In AD, amyloid-induced PV dysfunction disrupts gamma oscillations; in neurodegeneration, heterogenous proteinopathies (tau, α-synuclein, TDP-43) similarly impair PV interneuron survival and gamma generation. Hypothesis: TREM2 agonism combined with closed-loop PV stimulation will synergistically enhance gamma oscillations and slow cognitive decline in non-amyloid neurodegeneration, analogous to the amyloid-AD mechanism.

Analogy rationale: Both AD and neurodegeneration share TREM2-mediated microglial pathways and PV interneuron involvement in gamma generation, suggesting that restoring PV function through closed-loop optogenetics may generalize across proteinopathies despite different primary pathologies.

The AD mechanism of PV interneuron targeting to restore theta-gamma coupling may transfer to neurodegeneration via TREM2-microglial modulation of GABAergic inhibition. In AD, amyloid-induced PV dysfunction disrupts gamma oscillations; in neurodegeneration, heterogenous proteinopathies (tau, α-synuclein, TDP-43) similarly impair PV interneuron survival and gamma generation. Hypothesis: TREM2 agonism combined with closed-loop PV stimulation will synergistically enhance gamma oscillations and slow cognitive decline in non-amyloid neurodegeneration, analogous to the amyloid-AD mechanism.

Analogy rationale: Both AD and neurodegeneration share TREM2-mediated microglial pathways and PV interneuron involvement in gamma generation, suggesting that restoring PV function through closed-loop optogenetics may generalize across proteinopathies despite different primary pathologies.

Disanalogies: AD is driven by amyloid pathology whereas most neurodegeneration involves tau, α-synuclein, or TDP-43 with distinct temporal and spatial patterns; gamma deficits in AD correlate specifically with amyloid burden, whereas in Parkinson's or FTD they may reflect subcortical or network-level disruption not correctable by PV targeting alone.

Falsifiable prediction: In a tau or α-synuclein transgenic model, combined TREM2 agonism + closed-loop PV optogenetics will produce a >40% increase in gamma power (measured via LFP) and demonstrate cognitive rescue on spatial working memory tasks, with post-mortem validation of restored PV:excitatory neuron ratios—testable within 12 months.
This hypothesis was generated from `h-var-e95d2d1d86` in `Alzheimer's disease` — judge it on its own merits but acknowledge the source.